Celcuity

Celcuity is a biotechnology company developing and delivering new targeted therapies for cancers involving the PAM (PI3K/AKT/mTOR) pathway.

[Celcuity @celcuity]

Today Dr. Barbara Pistilli presented updated results from VIKTORIA-1 our pivotal Phase 3 study evaluating gedatolisib regimens in patients with HR+/HR2- advanced breast cancer in a late breaking rapid oral presentation at the ESMO Congress 2026. Read more: https://t.co/I73LcHoYLy

[Celcuity @celcuity]

Today Dr. Adam Sharp presented updated data from our Phase 1b/2 study evaluating gedatolisib plus darolutamide in men with metastatic castration-resistant prostate cancer in a poster session at the ESMO Congress 2026. Read more: https://t.co/7nwJddIBdd
$CELC

[Celcuity @celcuity]

We’re pleased to announce that David Gryska has joined our Board of Directors. With over 35 years of strategic and financial leadership experience in the pharmaceutical industry, David brings valuable expertise and perspective to $CELC. Welcome, David!
https://t.co/AMTbVbadLk

[Celcuity @celcuity]

Following our recent FDA approval, REVTORPYK™ (gedatolisib) is now commercially available in the U.S. Learn more about this important milestone and our commitment to supporting patients and healthcare providers in the full announcement. https://t.co/o3nutUzdVt

[Celcuity @celcuity]

$CELC CEO Brian Sullivan will participate in a fireside chat with Citi Equity Analyst Eva Fortea-Verdejo today. Listen to the webcast: https://t.co/TYjtkcyGFF

[Celcuity @celcuity]

$CELC will participate in the Wells Fargo and Citi Investor Conferences next week. Learn more: https://t.co/tQhHLeloWi

[Celcuity @celcuity]

We are very pleased to announce that Celcuity has submitted its supplemental NDA to the FDA for REVTORPYK™ (gedatolisib. You can find more details in the press release: https://t.co/2CMkh3Gmbs
$CELC

[Celcuity @celcuity]

Featured in @CancerNetwrk: a leading oncologist's perspective on the recent FDA approval of a new targeted therapy for patients with HR+/HER2-, PIK3CA wild-type locally advanced or metastatic breast cancer.

Read the full article: https://t.co/GYrqy9cADF

[Celcuity @celcuity]

Celcuity reports financial results for the second quarter 2026 and provides a corporate update today. Read our press release here: https://t.co/e2HgbLOAUn
Listen to our webcast conference call today at 4:30 pm ET: https://t.co/ysvwso1TjI
$CELC

[Celcuity @celcuity]

Celcuity will report on its second quarter 2026 financial results this Thursday, August 13, 2026. Celcuity management will host a webcast conference call at 4:30 pm ET. Learn more: https://t.co/ANVQW9JxGe
$CELC

[Celcuity @celcuity]

REVTORPYK™ (gedatolisib) in combination with fulvestrant, w/or/wo palbociclib, is recommended by the NCCN Clinical Practice Guidelines in Oncology as a preferred Category 1 second-line and/or subsequent-line therapy. Details in our press release: https://t.co/cIjr1i0Wq1 $CELC

[Celcuity @celcuity]

#NEWS: The FDA has approved our targeted therapy for patients with HR+/HER2-, PIK3CA wild-type locally advanced or metastatic breast cancer following progression on prior therapy. Learn more: https://t.co/5CRq2e4wiO
#FDAApproval
#BreastCancer
$CELC

[Celcuity @celcuity]

Listen in tomorrow morning as Celcuity CEO and co-founder Brian Sullivan participates in a fireside chat presentation with equity research analyst Rich Law the at Goldman Sachs 47th Annual Global Healthcare Conference in Miami. Webcast link: https://t.co/pEDPpWb1I2
$CELC

[Celcuity @celcuity]

Celcuity CEO Brian Sullivan will participate in a fireside chat with Equity Research Analyst Maury Raycroft at the Jefferies Global Healthcare Conference. Listen in: https://t.co/SdTVaUBANf
$CELC #JefferiesHealthcare

[Celcuity @celcuity]

Celcuity reported detailed results for the PIK3CA mutant cohort of the pivotal Phase 3 VIKTORIA-1 trial in patients with HR+/HER2- advanced breast cancer. Read our press release here: https://t.co/8c8yIR8p5R

[Celcuity @celcuity]

$CELC announced that we will host a conference call and live webcast to review results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial on Tuesday, June 2, 2026, at 8:00 a.m. EDT. https://t.co/oKrccneW3x

[Celcuity @celcuity]

We look forward to attending the upcoming conferences in June: Jefferies Global Healthcare Conference in New York and Goldman Sachs 47th Annual Global Healthcare Conference 2026.
For more information: https://t.co/tRBNAzWjqz
$CELC

[Celcuity @celcuity]

$CELC reports financial results for Q1 2026 and provides a corporate update today. Press release: https://t.co/euJ69vBHhF | Webcast at 4:30 pm ET: https://t.co/4wiscp94Z7

[Celcuity @celcuity]

$CELC announces updates to our clinical development plan including expansion of our Phase 3 VIKTORIA-2 clinical trial to include a second study evaluating gedatolisib as 1L treatment in patients with endocrine-sensitive HR+/HER2- advanced breast cancer. https://t.co/FKpP3TCZ4U

[Celcuity @celcuity]

$CELC will report on Q1 2026 financial results next Thursday, May 14, 2026. Celcuity management will host a webcast conference call at 4:30 pm ET. Learn more: https://t.co/dPvHaRGIeZ